(Q38003196)

26 August 2017

title

Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder (English)

1 reference

26 August 2017

1 reference

7

1 reference

26 August 2017

1

Gin S Malhi

1 reference

26 August 2017

6

Michael Bauer

1 reference

26 August 2017

5

Mark A Frye

1 reference

26 August 2017

3

Roger McIntyre

1 reference

26 August 2017

2

Danielle M Bargh

1 reference

26 August 2017

4

Michael Gitlin

1 reference

26 August 2017

language of work or name

1 reference

1 May 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

14 Suppl 2

1 reference

26 August 2017

page(s)

1-21

1 reference

The long-term natural history of the weekly symptomatic status of bipolar I disorder

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Bipolar disorder: new perspectives in health care and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Sustained unemployment in psychiatric outpatients with bipolar disorder: frequency and association with demographic variables and comorbid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Suicide risk in bipolar patients: the role of co-morbid substance use disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Grand challenges in global mental health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Comorbid anxiety and substance use disorders associated with a lower use of mood stabilisers in patients with rapid cycling bipolar disorder: a descriptive analysis of the cross-sectional data of 566 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Psychotherapy for bipolar disorders - efficacy and effectiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Clinical practice recommendations for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A collaborative approach to the treatment alliance in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Enhancing medication adherence in patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

New treatment guidelines for acute bipolar depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Medicating mood with maintenance in mind: bipolar depression pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy of antimanic treatments in mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Treatment options for acute depression in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Maintenance therapies in bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Hypomania: hype or mania?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Psychosocial Disability in the Course of Bipolar I and II Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Lithium: still a cornerstone in the long-term treatment in bipolar disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Valproate for acute mood episodes in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Suicidal behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A prospective study of the impact of subthreshold mixed states on the 24-month clinical outcomes of bipolar I disorder or schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Towards a reconceptualization of mixed states, based on an emotional-reactivity dimensional model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Secular trends in first hospitalizations for major mood disorders with comorbid substance use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Clinical characterization of depressive mixed state in bipolar-I patients: Pisa-San Diego collaboration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months--European mania in bipolar longitudinal evaluation of medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Differences in incidence of suicide attempts during phases of bipolar I and II disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Risperidone in the treatment of acute mania: double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Improving treatment adherence in bipolar disorder: a review of current psychosocial treatment efficacy and recommendations for future treatment development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

The clinical management of bipolar disorder complexity using a stratified model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Suicide risk in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Safety and tolerability of emerging pharmacological treatments for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Treatment adherence with antipsychotic medications in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Atypical antipsychotic tolerability and switching strategies in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

The lithiumeter: a measured approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Antidepressants for bipolar depression: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Tapering antidepressants: is 3 months slow enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Is depressive mixed state a transition between depression and hypomania?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Latest maintenance data on lamotrigine in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A pilot study of topiramate as monotherapy in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Clozapine in the treatment of refractory psychotic mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Maintenance efficacy of divalproex in the prevention of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Misdiagnosed Patients With Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Drs. Suppes and Vieta Reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

Quetiapine dosage in bipolar disorder episodes and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00989.X

10.1111/J.1399-5618.2012.00989.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference